Compounding Pharmacies & Drug Pricing - HIMS's ownership of compounding pharmacies enables the sale of compounded medications at significantly reduced prices [1] - Nova Nordisk and Eli Lilly justify their drug prices based on R&D investments and sophisticated injector pens [1] - Compounded drugs are mixed from active ingredients and lack sophisticated injector pens, using vials and syringes instead [2] - Compounded drugs bypass the rigorous FDA testing for safety and efficacy, contributing to their lower prices [3] Regulatory & Approval Status - Compounded drugs are not FDA-approved [2] - Compounded drugs do not undergo the same safety and efficacy testing as FDA-approved drugs [3] Market Positioning - The report focuses on how HIMS became a major player in knockoff weight loss drugs [3] - The report questions HIMS's future if it cannot maintain its dominance in the market [3]